GeoVax Labs, Inc. (GOVX)
NASDAQ: GOVX · IEX Real-Time Price · USD
1.650
+0.060 (3.77%)
At close: May 6, 2024, 4:00 PM
1.620
-0.030 (-1.82%)
After-hours: May 6, 2024, 7:59 PM EDT
GeoVax Labs Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
3.81M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 81.53K | -303.98K | -78.85% |
Dec 31, 2021 | 385.50K | -1.44M | -78.86% |
Dec 31, 2020 | 1.82M | 647.76K | 55.09% |
Dec 31, 2019 | 1.18M | 212.69K | 22.08% |
Dec 31, 2018 | 963.20K | -112.07K | -10.42% |
Dec 31, 2017 | 1.08M | 246.35K | 29.72% |
Dec 31, 2016 | 828.92K | 400.84K | 93.64% |
Dec 31, 2015 | 428.08K | -454.88K | -51.52% |
Dec 31, 2014 | 882.96K | -1.53M | -63.48% |
Dec 31, 2013 | 2.42M | -239.78K | -9.02% |
Dec 31, 2012 | 2.66M | -2.24M | -45.77% |
Dec 31, 2011 | 4.90M | -285.37K | -5.50% |
Dec 31, 2010 | 5.19M | 1.52M | 41.36% |
Dec 31, 2009 | 3.67M | 758.03K | 26.05% |
Dec 31, 2008 | 2.91M | 2.67M | 1,127.90% |
Dec 31, 2007 | 237.00K | -615.90K | -72.21% |
Dec 31, 2006 | 852.91K | 182.44K | 27.21% |
Dec 31, 2005 | 670.47K | -44.39K | -6.21% |
Dec 31, 2004 | 714.85K | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2001 | 2.62M | 1.76M | 204.73% |
Dec 31, 2000 | 859.84K | -1.42M | -62.27% |
Dec 31, 1999 | 2.28M | -3.09M | -57.54% |
Dec 31, 1998 | 5.37M | 2.64M | 96.61% |
Dec 31, 1997 | 2.73M | - | - |
Dec 31, 1996 | 2.73M | 2.64M | 2,805.93% |
Dec 31, 1995 | 93.95K | -9.51M | -99.02% |
Dec 31, 1994 | 9.60M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGOVX News
- 4 weeks ago - GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine - GlobeNewsWire
- 5 weeks ago - GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress - GlobeNewsWire
- 7 weeks ago - GeoVax to Present at the 36th Annual Roth Conference - GlobeNewsWire
- 2 months ago - GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System - GlobeNewsWire
- 2 months ago - GeoVax Reports 2023 Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 - GlobeNewsWire
- 2 months ago - GeoVax to Present at the 2024 BIO CEO & Investor Conference - GlobeNewsWire
- 2 months ago - GeoVax Announces Multiple Patent Issuances and Allowances - GlobeNewsWire